Brigham and Women’s Hospital Clinical Investigators from Harvard Medical School, in the United States, are preparing the trial of a nasal vaccine designed to prevent and delay the progress of Alzheimer disease.
According to the official site of the hospital Hospital Brigham and Women’sOver the last 20 years, research on Alzheimer’s disease has been developed that led to the nasal vaccine.
This will be the first time you have experimented with a nasal Alzheimer’s vaccine, a type of degenerative dementia that eliminates neural connections that prevent the patient from accessing short and long-term memories.
The launch of the first human trial of a nasal vaccine for Alzheimer’s it’s a remarkable milestone, “said Howard L. Weiner, co-director of the Ann Romney Center.
This rehearsal will have the participation of 16 participants between 60 and 85 years of age.
Several of the participants in this trial have history of Alzheimer’s or they are part of the control group who have not shown any symptoms or antecedents of the disease.
How is a nasal vaccine administered?
The how a vaccine works nasal consists of an application as in the case of a spray when we have the flu.
The particles of the compound with which the vaccine is made seek to prevent the onset of Alzheimer’s.
The immune system plays a very important role in all neurological diseases, “Weiner said.
emb
– .
